RxDoctor Payments Data

Kerry Takeda, APRN

Primary Care · la Vista, NENPI 1811681497

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 197 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,738in general payments, 2019–2025

Across 197 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$529
  • AstraZeneca$287
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$270
  • Lilly USA, LLC$253
  • Otsuka America Pharmaceutical, Inc.$241
  • Aimmune Therapeutics, Inc.$224
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$3,738100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,738 in reported general payments places this provider in the 90th percentile of 65 primary care providers in Nebraska.

See all primary care providers in Nebraska

Medicare billing

Part B allowed, 2024
$31,225
Medicare patients
141
Services billed
546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide25$28,687
JardianceEmpagliflozin17$22,763
Roflumilast11$1,654
Nebivolol Hcl18$933
Celecoxib35$550
Albuterol Sulfate HfaAlbuterol Sulfate14$450
Metformin Hcl ErMetformin Hcl20$288
Clonazepam15$231
Gabapentin24$207
Levothyroxine Sodium38$200
Pantoprazole Sodium36$195
Valsartan19$149
Losartan Potassium16$131
Escitalopram Oxalate19$129
Trazodone Hcl29$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$253$28,68725 claims
Boehringer IngelheimJardiance$63$22,76317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 65 primary care providers in Nebraska.

Other primary care in la Vista

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →